Insights into Newly Approved Drugs from a Medicinal Chemistry Perspective

Title:Insights into Newly Approved Drugs from a Medicinal Chemistry Perspective

Volume: 21 Issue: 16

Author(s): Elys Juliane Cardoso Lima, Renan Augusto Gomes, Evelin Fornari, Flavio da Silva Emery and Gustavo Henrique Goulart Trossini*

Affiliation:

• Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo,Brazil

Keywords: Drug design, medicinal chemistry, new molecular entities, FDA-approved drugs, structure-based drug design, SBDD, ligand-based drug design, LBDD, fragment-based drug design, FBDD.

Abstract: The development of new drugs is becoming notably harder each decade. To overcome the present pitfalls in the drug development pipeline, such as those related to potency, selectivity, or absorption, distribution, metabolism, excretion and toxicity properties, medicinal chemistry strategies need to be in continuous evolution and need to become even more multidisciplinary. In this review, we present how structure-based, ligand-based, and fragment-based drug design (SBDD, LBDD, and FBDD, respectively) and their respective techniques were used for the design and optimization of successful cases of New Molecular Entities (NMEs) approved by the Food and Drug Administration (FDA).

Cite this article as:

Lima Juliane Cardoso Elys , Gomes Augusto Renan , Fornari Evelin, da Silva Emery Flavio and Trossini Henrique Goulart Gustavo *, Insights into Newly Approved Drugs from a Medicinal Chemistry Perspective, Mini-Reviews in Medicinal Chemistry 2021; 21 (16) . https://dx.doi.org/10.2174/1389557521666210226145328